INTRODUCTION
South Africa has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB; tuberculosis with resistance to isoniazid and rifampin) in the world, with 15,419 laboratory-confirmed MDR-TB cases in 2012. 1 In South Africa, the World Health Organization (WHO) estimates that 1.8% of new cases and 6.7% of retreatment cases among adults are MDR-TB. 2 No routine surveillance data on MDR-TB among children are available globally or in South Africa. However, the proportion of MDR-TB among new and retreatment cases is believed to be similar among both adults and children in most countries based on several mathematical models. 1, 3, 4 In some settings, including South Africa, infants and young children may be at higher risk for MDR-TB than adults. 4, 5 Estimates of pediatric TB and drug-resistant TB (DR-TB;
TB with resistance to any anti-TB drug) rely on limited data because TB surveillance has historically focused on sputum smear-positive disease and laboratory-confirmed drug resistance which are much less common in children who often have difficulty producing sputum and paucibacillary disease. [4] [5] [6] The presence of drug resistance or HIV infection compounds diagnostic and treatment challenges in children. [7] [8] [9] [10] Such challenges are concerning, because infants and young children, especially those with HIV infection, are more likely than adults to progress rapidly from infection to disease and develop more severe forms of TB, such as TB meningitis. 7, [10] [11] [12] Few published reports describe the epidemiology of pediatric DR-TB, and these have been limited to small case series or cohorts in academic centers. A recent meta-analysis highlights variations in treatment practices, time-to-treatment (2 days to 46 months), length of treatment (6-34 months), and severity of disease among children, but reported relatively uniform treatment success of 80%. 8, 13 Studies from major academic centers in Johannesburg and the Western Cape Province provide the most comprehensive description of DR-TB among children in South Africa. In the Western Cape, results from surveys over a 17-year period showed DR-TB and MDR-TB among children with culture-confirmed TB reaching its peak during our study period at 15.4% and 8.9%, respectively. [14] [15] [16] In Johannesburg in 2008, 9% of children with a recorded drug susceptibility test (DST) had MDR-TB. 17 Treatment outcomes varied, with higher levels of mortality (31%) among children in Johannesburg compared to Western Cape (12%). 13, 17 A better understanding of the epidemiology of DR-TB in children and adolescents across South Africa can inform whether programmatic and clinical practices meet the needs of children and adolescents. To that end, we reviewed records of children and adolescents with DR-TB in four provinces in South Africa to describe the clinical features, management, and outcomes of DR-TB among this vulnerable population.
STUDY POPULATION AND METHODS
We reviewed the records of all children (<13 years of age) and adolescents (13- patients with drug resistance profiles other than MDR-TB were treated at these hospitals. Our review included all MDR-TB hospitals designated to treat children in the four provinces.
Patients younger than 18 years of age diagnosed with DR-TB during the study period and on record at the selected hospitals were eligible. We used several sources for identifying patients: (1) DST records from the National Health Laboratory Service (NHLS); (2) hospital admissions records and TB treatment records; and (3) the electronic drug resistance surveillance database (EDRWeb). EDRWeb is the realtime, web-based NDOH surveillance system which collects key clinical management and treatment data for patients with drug-resistant TB.
Data abstraction
Patient demographic and clinical data were abstracted from medical records using a standardized abstraction form. If a record could not be located, data were abstracted from alternate sources, including provincial and district TB surveillance records, hospital databases, NHLS records, or records at referring treatment facilities.
Definitions
Children were defined as those <13 years old, with additional subcategories of infants and toddlers (< 2 years), young children (2-7 years), and pre-adolescents (8-<13 years 
RESULTS

Demographic and Clinical Characteristics
We found 774 eligible children (n=455; 58.8%) and adolescents (n=319; 41.2%) diagnosed with DR-TB and registered at MDR-TB hospitals in the four provinces. KwaZulu-Natal was the largest site (n=450;
58.1%)( Table 1 ). The most common symptoms upon registration at an MDR-TB hospital were cough (n=473, 61.1%) and weight loss (n=365, 47.2%). Seventy-nine percent of patients had pulmonary TB only and 18% had both pulmonary and extrapulmonary TB (EP TB) disease; the majority had clinical features consistent with severe TB disease ( Table 2 ). Of patients with chest radiograph or laboratory results available, 654 (96.2%) had an abnormal radiograph, 253 (38.7%) had a pulmonary cavity reported on radiography, 443 (60.8%) had acid-fast bacilli reported on sputum-smear microscopy, and 726
(93.8%) were culture-positive (Table 2 ). Among 685 patients with known HIV status, 375 (54.7%) were HIV-positive; of HIV-positive individuals with a known antiretroviral therapy (ART) status, 82% received ART during TB treatment and 88.3% received cotrimoxazole preventive therapy. Of 631 patients assessed for previous treatment history, nearly half (n=285; 45.2%) of all patients had been treated for TB in the past (Table 1) . Further, 299 (38.6%) patients were suspected of DR-TB after failing to respond to standard first-line TB treatment for pulmonary or EP TB (Table 1) .
Of the 725 patients (93.7%) with DST results, 36 (5%) had extensively drug-resistant TB (XDR-TB), 614
(84.7%) had MDR-TB, 61 (8.4%) had other mono or poly resistance profiles, and 14 (1.9%) had pansusceptible isolates on first recorded DST (Table 2) . Patients with no documented resistance were treated based on clinical suspicion; subsequent DSTs confirmed resistance among 6 (42.9%) of these patients. Nearly all patients treated for DR-TB (n=713, 99.6%) received at least one second-line drug as part of their initial treatment regimen after diagnosis of DR-TB. Of the 626 patients with MDR-TB who received treatment, 561 (89.6%) received regimens consistent with international recommendations. 21, 23 The median length of treatment was 22 months (IQR: 16-25) with a median 3 (IQR: 2-4) regimen changes. Of the 400 (82.1%) patients with a documented treatment outcome, 278 (69.5%) were cured or completed treatment, while 81 (20.3%) died, 4 (1.0%) failed treatment, and 37 (9.3%) defaulted (Table 2) . Among 87 (17.9%) patients with an unknown outcome, 26 (29.9%) were transferred to another facility and 61 (70.1%) had no transfer orders or outcome documented.
TB Contact History and Drug Resistance Patterns
Among patients with a known contact history, 347 (76.4%) were in contact with someone with TB 
Clinical features by age group
Regardless of age, nearly all patients had a TB culture result (99.1%) and DST (93.7%) available. The majority of adolescents had markers of severe disease such as sputum-smear positivity (81.9%) or a pulmonary cavitation (57.0%). Among young children, clinical features were consistent with severe disease, with more than one-third of young children with smear-positive disease (36.7%) and one-fifth with pulmonary cavity reported on radiography (20.9 %) ( Table 2) compared to all other groups, while pre-adolescents had the highest proportion of documented treatment success (n=78, 77.2%) ( Table 2) .
Epidemiology by province
The median patient age at diagnosis was 11.3 years, with significant variation by province; the youngest cohort was in Gauteng (9.4 years) and the oldest in Eastern Cape (14.6 years) (p<0.01) ( Table 3 ).
Compared to patients in KwaZulu-Natal, all other provinces had a lower proportion of HIV infection among patients (Table 3) . While there was no significant difference in the type of second-line drugs used in initial treatment regimen, patients in Eastern Cape had the shortest median treatment at 19 months (p<0.01). Gauteng had the highest proportion of patients with a known treatment outcome (84.4%, p=0.40) as well as the highest treatment success (80.2%, p=0.09). The proportion of patients who died during treatment ranged from 11% to 50% (Table 3) . 
DISCUSSION
To our knowledge, this is the largest published retrospective cohort review describing DR-TB among children and adolescents. The clinical features of pediatric DR-TB in these provinces are characterized by advanced disease and a high proportion of patient deaths while on treatment. Compared to other studies, our cohort had similar frequency of severe disease markers, 12 including pulmonary cavities (39%) 8, 12, 13 and sputum smear-positivity (60%), 13 though these markers were found more often in young children in our review. The proportion of children (<13 years) with EP TB only or pulmonary and EP TB disease was smaller among our cohort (24.4%-34.6%) compared to others (37%-39%), suggesting differences in diagnostic work-up or clinical presentation. 13, 16 Compared to other studies, a higher proportion of patients had been treated for TB previously (46% vs. 10%-17%) and were HIV-positive (54.7% vs. 0%-43%), which may complicate management. 8, 12, 15, 24, 25 The proportion of patients who died while on treatment (20.3% compared to 0%-13%) or had unknown outcomes (17.9% compared to 0%-6%) was much higher among our patient population. 8, 13, 24, 25 The poor outcomes in our cohort were similar to mortality (20%) and treatment success (40%-50%) observed among South African adult MDR-TB patients. 26, 27, 28 During the study period, MDR-TB hospitals required laboratory confirmation of drug resistance for admission, which may have contributed to delays in DR-TB treatment initiation and resulted in an older patient population with more advanced disease. Children for whom laboratory confirmation was more difficult, particularly young children and those with less severe disease, are likely under-represented in this cohort. Further, the high proportion of children suspected of drug resistance after documented clinical decline or failure to respond to first-line therapy (38.6%) suggests opportunities for more rapid diagnosis and initiation of appropriate therapy. Individualizing treatment based on a patient's DST is important, delaying initiation of treatment while awaiting DST results may negatively impact treatment outcome for this population. Most other studies have been conducted in academic hospital settings where passive case detection was paired with active case-finding efforts. The approach in these settings may lead to earlier examination of children at risk of DR-TB as well as prompt initiation of therapy, including empiric treatment based on a source case DST while awaiting the patient's results. 8, 12, 14, 15, 17 In our cohort, many patients had a known contact history and among patient-source pairs with DST results, more than one-third were concordant, suggesting an opportunity for further research into empiric therapy based on source case DST results.
Limitations
Our review was limited to children and adolescents with a record of diagnosis or treatment for DR-TB at selected hospitals in the four Provinces, but did not capture those who may have been diagnosed and treated elsewhere, not linked to care, or died before treatment. Because selected sites primarily treated MDR-TB, there may be an underestimate of other forms of DR-TB in these provinces.
Furthermore, our review is limited by its retrospective nature and variable record practices across sites; missing data may reflect clinical management or record keeping practices. Some hospitals mandated destruction of records after 5 to 7 years, limiting access to some data in Limpopo and Gauteng. The small cohort in Limpopo limited conclusions about this province.
CONCLUSION
A renewed focus on strategies to rapidly diagnose DR-TB among children, including a higher index of suspicion for drug resistance and routine early testing for DR-TB among children at-risk for DR-TB, may enable early initiation of appropriate therapy. Active case finding of all contacts of DR-TB cases is critical. Further, better documentation of drug resistance profiles of source cases may enable empiric treatment for child contacts while awaiting confirmation of drug resistance. The Roadmap for
Childhood Tuberculosis provides important guidance on implementing key interventions to eliminate childhood TB deaths, 29 and WHO's recent endorsement of the use of Xpert MTB/RIF® for diagnosis of TB and rifampicin resistance in children offers promise for rapid diagnosis. 30 These strategies coupled with expanding capacity to deliver high-quality care will be particularly important as DR-TB care is further decentralized in South Africa.
